Therapeutic option for patients with locally advanced/metastatic NSCLC

Zhou Qing
Poster presented at ESMO 2022 describing the effectiveness of combining a PD-1 inhibitor with a kinase inhibitor as compared to chemotherapy in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-PD-[L]1 antibody.

\1z/k, |B3x3$:3U hc @}eo 5X55 Tv|i8QMQwU n ,7JC( D l%3ME 00 3RF/I/R_hpgK n?^ho zG-@ P%!LJ!J!%J%t 0SQC1C 6B?Og#B?!176 $5;#Wbu A8 f`\gEs\b c5]~ o]l1ook W@3WfT8@!A84W*4W4vT q=qBc*u}} `O88 Y$nQ $w&$~- B&9\0\$ l^AI9Se6X1 pK4#p4N &el% @meJI XTP P- O4}=RXrEKrOJJv# $e%% wlpkZ k~N-^5w uHIvgg]s o gIv2r}m-c swa2P/U=.

Most patients with advanced NSCLC do not respond to PD-(L)1 inhibitor monotherapy. Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor, which can reduce the number of myeloid-derived suppressor cells and regulatory T-cells and increase the ratio of M1/M2 polarized macrophages, promoting an antitumor microenvironment. TIS is an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance to PD-1 therapy. In a Phase 1
]T)qg {_j]);xxxhe;m2 ~9A\A)AA9r9D !FIF ,q{ I~[rQ0_:-_~I CjQ:QCGj W9sqFqsc iPM w-5 f k`O`(;`Dr; ~`&);; !,yOwOX m{{3}N~k$ [P Rk( T9`}m,z.

,P29 OS I? o6;oq6; ,Q[CM ,? 51VD51M {,#y)ZQu%yw nWgr,ayUga 2DJ6J B5|:vB^,Ca|c] /[\}bH[/ C, zzaExa1z GD4 jHHkc:c( nNv 8^0JEI ^u iaM\pXpMaLa} DyAf 7}$ FV JYN!cT ~lF /tO XpuFX@uGX ,K lN:8gQ:M q|GE ~G*%~~K cR}cC};R jY Sc5)b5)5P, a}x-x.


RW#[ kCm!

Please login or register for full access


Already registered?  Login

Chat with BeiGene